Divergent Planning LLC Takes Position in Eli Lilly and Company $LLY

Divergent Planning LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,986 shares of the company’s stock, valued at approximately $1,548,000.

A number of other institutional investors have also recently bought and sold shares of the business. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last quarter. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Berenberg Bank restated a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $808.88 on Tuesday. The firm has a market capitalization of $765.57 billion, a price-to-earnings ratio of 52.87, a PEG ratio of 1.15 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business’s 50-day moving average price is $756.56 and its 200-day moving average price is $766.20. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business earned $3.92 EPS. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.